tesamorelin
How Vial Fill Volume Claims Compare Across Tesamorelin Listings
A guide to reading tesamorelin vial fill volume claims, how they relate to labeled mass, reconstitution math, and what a COA should confirm.
Medically reviewed by Catherine Dumont, MD, physician and clinical researcher — Last reviewed
Catherine Dumont, MD is a physician with clinical and research training in endocrinology and growth hormone therapeutics, with post-graduate research in GHRH analog applications and growth hormone axis disorders.
Tesamorelin listings describe vials in at least three different ways, and figuring out how vial fill volume claims compare across tesamorelin listings starts with separating three numbers that get blurred together on product pages: the labeled peptide mass, the lyophilized fill inside the vial, and the liquid volume added later during reconstitution. A listing that states “2 mg vial” is describing dry mass, not a volume at all — the vial has no meaningful “fill volume” until bacteriostatic water is added. Confusion between these terms is one of the most common sourcing errors, and it changes the resulting concentration if it goes unnoticed.
What “fill volume” actually refers to
In lyophilized peptide products, the vial itself typically contains a small amount of freeze-dried powder or cake, not a liquid. Some suppliers list a “fill volume” as a manufacturing specification — the volume the solution occupied before freeze-drying, which correlates loosely with cake size and vial headspace, but is not the volume a researcher will draw at reconstitution. Other listings use “fill volume” loosely to mean “how much bacteriostatic water should be added,” which is a reconstitution instruction, not a property of the vial as shipped. When comparing listings, the first task is identifying which of these two meanings a given page intends, because they answer different questions.
A rigorous listing separates these clearly: labeled mass (mg), any manufacturing fill-volume specification (if disclosed), and a suggested reconstitution volume. A listing that only says “2 mg” and nothing else is not incomplete by definition — reconstitution volume is a researcher’s choice — but a listing that uses “fill volume” and “reconstitution volume” interchangeably without defining either is a sign of inconsistent internal documentation.
Why the distinction changes the concentration math
Concentration depends entirely on how much diluent is added relative to labeled mass, not on any manufacturing fill specification. The relationship is:
Concentration (mg/mL) = vial mass (mg) ÷ volume of bacteriostatic water added (mL)
Consider a 2 mg vial. If a researcher adds 2 mL of bacteriostatic water, the concentration is 2 mg ÷ 2 mL = 1 mg/mL. If the same 2 mg vial is reconstituted with 1 mL instead, the concentration becomes 2 mg ÷ 1 mL = 2 mg/mL — double the strength, using the identical vial. Checking this twice: 2 divided by 2 is 1, and 2 divided by 1 is 2. Both check out. This is why a listing’s stated “fill volume” is close to irrelevant to potency calculations unless it is explicitly the reconstitution volume being recommended — the manufacturing fill and the researcher’s added diluent are two different volumes serving two different purposes.
Expressed in mcg, the same 2 mg vial equals 2000 mcg (1 mg = 1000 mcg). At 1 mg/mL, each 0.01 mL marked on a U-100 insulin syringe (1 unit) delivers 1000 mcg ÷ 100 units = 10 mcg per unit, since a U-100 syringe marks 1 mL as 100 units. At 2 mg/mL, that same syringe unit delivers 20 mcg. Recomputing: 2000 mcg ÷ 2 mL = 1000 mcg/mL, divided by 100 units = 10 mcg/unit — confirmed. And 2000 mcg ÷ 1 mL = 2000 mcg/mL ÷ 100 units = 20 mcg/unit — also confirmed. The two-fold difference in diluent produces a precise two-fold difference in per-unit concentration, which is why the diluent volume, not the vial’s manufacturing fill claim, is the number that determines dosing math downstream.
Comparing how listings present this information
| Listing element | What it should specify | Common ambiguity |
|---|---|---|
| Labeled mass | mg of tesamorelin per vial | Sometimes given as a range or “up to” figure |
| Manufacturing fill volume | Pre-lyophilization solution volume (if disclosed at all) | Often omitted; rarely relevant to end use |
| Suggested reconstitution volume | mL of bacteriostatic water recommended | Sometimes absent, left to the researcher |
| Resulting concentration | mg/mL or mcg/unit at a stated reconstitution volume | Calculated only if reconstitution volume is stated |
| COA batch match | Confirms mass tested corresponds to the labeled vial | Sometimes a generic COA not tied to the specific lot |
A listing that fills in every row of this table with a specific, internally consistent number is easier to verify than one that states only a headline mg figure. When a listing advertises a concentration (for example, “1 mg/mL”) without stating the reconstitution volume it assumes, that figure cannot be checked against the labeled mass and should be treated as unverified until the underlying volume is disclosed.
What a batch-specific COA should confirm
A certificate of analysis tied to the specific lot number on the vial is the reference point for the labeled mass claim, independent of how the listing describes fill volume. The COA typically reports purity by HPLC and may report mass by weight or by a calculated peptide content percentage. None of this addresses reconstitution volume, because reconstitution happens after the vial leaves the manufacturer — it is a downstream step under the researcher’s control, not a manufacturing spec. A solid listing keeps these categories distinct: the COA answers “does the labeled mass match what’s actually in the vial,” while the reconstitution instructions answer “what concentration results from a given amount of diluent.” Conflating the two, or expecting the COA to validate a reconstituted concentration, is a sourcing error worth avoiding.
Vial format also affects how fill claims should be read. Single-use vials intended for one reconstitution event typically match their labeled mass directly to a COA. Multi-dose vial formats, where a larger mass is packaged for reconstitution into a larger diluent volume, require checking whether the labeled mass refers to the whole vial or a per-dose fraction — another point where listings vary in clarity.
Questions worth asking before comparing across suppliers
Before treating two listings as directly comparable, it helps to check whether both state labeled mass in the same unit (mg versus mcg, which differ by a factor of 1000), whether either discloses a manufacturing fill volume versus a reconstitution volume, and whether any advertised concentration figure states the diluent volume it assumes. Listings that leave these values implicit are not necessarily wrong, but they push the verification work onto the researcher, who then has to work backward from a COA and a labeled mass to determine what a stated concentration actually means.
Summary
Fill volume claims on tesamorelin listings can refer to a manufacturing specification, a suggested reconstitution volume, or be used loosely to mean either, and only the reconstitution volume actually chosen determines the resulting concentration. Comparing listings meaningfully means checking that labeled mass, any stated reconstitution volume, and the resulting mg/mL or mcg/unit figures are all self-consistent, and that a batch-specific COA supports the labeled mass independent of any reconstitution claim.
Sources referenced in the study of tesamorelin and related GHRH analogs include a Phase 1 pharmacokinetics and pharmacodynamics study of TH9507 in HIV-positive patients, a study on CJC-1295, a long-acting GHRH analog, and its effect on serum protein profiles, and a placebo-controlled extension study assessing long-term safety of a 2 mg TH9507 dose in HIV subjects with abdominal fat accumulation.